LGDN:FRA
Ligand Pharmaceuticals Inc
190.00 €
0.00%
(0.00) יום
24 באפר׳, 22:00:00 GMT+2 · EUR
search
כל הסמלים
יום
5 ימים
חודש
6 חודשים
YTD
שנה
5 שנים
מקסימום
| סמל | מחיר | שינוי | אחוז השינוי |
|---|
insights_autoהמערכת יוצרת רשימת תובנות עיקריות לגבי LGDN…
פתיחה
192.00 €
גבוה
192.00 €
נמוך
190.00 €
שווי השוק
4.63B
נפח ממוצע
3.00
נפח
0.00
שיא של 52 שבועות
195.00 €
שפל של 52 שבועות
87.00 €
מספר העובדים
47
חדשות
ממקורות שונים מרחבי האינטרנט
פרופיל
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
מידע על Ligand Pharmaceuticals Inc
מנכ"ל/ית-
מספר העובדים47
תאריך ההקמהספט׳ 1987
המשרדים הראשייםג'ופיטר, פלורידה, ארצות הברית
מגזר-
אתרligand.com